
ç§ãã³ãããã¯ã¯ãã³ããæããªãïŒã€ã®çç±
ãææ¥ããã³ãããŠã€ã«ã¹ãã¯ã¯ãã³ããšããŠå»çåŸäºè ã«æ³šå ¥ãéå§ããããã¡ã€ã¶ãŒç€Ÿã®ãã®åããã³ãããã£ç泚ãã
ãå»çåŸäºè ã¯ãåªå æ¥çš®ãããããã
ãç§ã¯æããªãããšãéžæããã
ãçç±ã¯ïŒã€
â ã¡ãªããããªããã
â¡ãªã¹ã¯ã倧ãããã
â¢ããããã¯ã¯ãã³ã§ã¯ãªããã
ãã ã
â ã¡ãªããããªããã
ãæ°åã³ãããŠã€ã«ã¹ãã¯ã¯ãã³ãã«ã¯ã¡ãªããããªãã
ãçç±ã¯ãããïŒã€
1. å€ãã®æ¥æ¬äººãæ¢ã«çãŠã€ã«ã¹ã«æŽé²ããå
ç«ãæã£ãŠãããã
2. æ¢ã«äžççã«åæã«åãã£ãŠãããã
3. ã€ã¹ã©ãšã«ã§ææè ã»æ»è ãæ¿å¢ãããã
ãã§ããã
1. å€ãã®æ¥æ¬äººãæ¢ã«çãŠã€ã«ã¹ã«æŽé²ããå ç«ãæã£ãŠãããã
ãã¯ã¯ãã³ãšã¯æ¬æ¥ãŸã æŽé²ããŠããªããŠã€ã«ã¹ã现èã«å¯ŸããŠå
ç«ãã€ãããã®ã ã
ãæ°åã³ãããŠã€ã«ã¹ããšSARS-cov-2ã¯ãã»ãŒå
šãŠã®æ¥æ¬äººããã§ã«æŽé²ããŠãããšèãããããããã¯ææå¯Ÿçãªã©å§ãŸããã£ãšåã®2019幎12æã1æã«ãããŠã ã
ããã®ã°ã©ãã®èµ€ç·ã¯æšã·ãŒãºã³ã®ã€ã³ãã«ãšã³ã¶ã®æµè¡ã瀺ãããã®ã ã幎æ«å¹Žå§ããã¬ã¯ããšæžã£ãŠã»ãŒæ¶æ» ããŠããŸã£ãã
ãç¹°ãè¿ããããã¯ææå¯Ÿçãå§ãŸãããïŒã¶æåã®ããšãããŸã ã«ãææå¯Ÿçãã€ã³ãã«ãšã³ã¶ãæžãããããšãã人ãå€ããæç³»åãéã ã
ããã®é ãã€ã³ãã«ãšã³ã¶æ€æ»ã§é°æ§ã®é¢šéªãæµè¡ã£ãŠãããç§ã®èšºççµéšã§ã¯ãã€ã³ãã«ãšã³ã¶ã«æ¯ã¹ãŠé«ç±ã¯åºã«ãããå³ããã€ããé·åŒãåŸåããã£ããèªåãæšå¬ããã£ããšããèšæ¶ããã人ãå€ãã ããã
ããã®é¢šéªã¯COVID-19ã§ãã£ããšèããã®ãèªç¶ã ãèšåºçç¶ã»CTç»åã»é«éœ¢è
ã®æ¥å€ãããããããããäžèŽããã
ããã®çŸè±¡ã¯æ¥æ¬ã ãã§ã¯ãªãäžçåå°ã§èµ·ãã£ãŠããã
ãæç®çã«ã2019幎9æã®ã€ã¿ãªã¢ã®è¡æ¶²ã®10%以äžããæ°åã³ãããŠã€ã«ã¹ã®æäœãèŠã€ãã£ãŠãããªã©ãæŠæŒ¢ã¢ãŠããã¬ã€ã¯ä»¥åã«äžççã«SARS-cov-2ãååšããããšã蚌æãããŠããã
ãã€ã³ãã«ãšã³ã¶ã倧ããæžã£ãçç±ã¯ããã®æ°åã³ãããŠã€ã«ã¹ã«ãããŠã€ã«ã¹å¹²æžä»¥å€ã«ã¯èŠã€ãããªããïŒãããªãæç€ºããŠã»ããïŒ
ããããŠäŸå¹ŽçŽ2000äžäººãçºçã1000äžäººãå蚺ãããšãããã€ã³ãã«ãšã³ã¶ã倧ããæžãããã«ã¯ããŠã€ã«ã¹å¹²æžãåœæ°ã®å€§å€æ°ã§èµ·ãããªããŠã¯ãªããªãã
ãã
ãã€ãŸãæ¥æ¬ã§ã¯2019幎12æã2020幎1æã«ã€ã³ãã«ãšã³ã¶ã倧ããæžã£ãäºå®ããæ¥æ¬äººã®å€ããæ°åã³ãããŠã€ã«ã¹ã«æŽé²ãããããšãæå³ããã
ããšããããšã¯æ¢ã«ã»ãšãã©ã®æ¥æ¬äººã¯SARS-cov-2ã®å ç«ãæã£ãŠããããšã«ãªããããã¯ãã®åŸãPCRéœæ§ã§ãïŒå²ãç¡çç¶ã軜çã§ããçç±ã®äžéšã説æããã
ãæ¥æ¬äººã®æäœä¿æçã¯äœããã代ããã«åŸæ¥ã®ã³ãããŠã€ã«ã¹ã«å¯ŸããçŽ°èæ§å ç«ã®å ç«èšæ¶ãæã¡ãããã¯SARS-cov-2ã«ãæå¹ã§ããããšãããã£ãŠããã
ãæ¢ã«çã®ãŠã€ã«ã¹ãã®ãã®ã«æŽé²ãããŠå
ç«ãæã£ãŠããã®ã ãããçã¯ã¯ãã³ãæ¥çš®æžã¿ãšèããŠãããã
ã仿Žã¯ã¯ãã³ãæã€ããšã¯ïŒæéåã«éã£ãéšã«åããããããªãã®ãªã®ã ã
2. æ¢ã«äžççã«åæã«åãã£ãŠãããã
ãã§ã¯ãªããã®åŸãææè ã»æ»è ãåºãã®ãïŒãšããçåãæ¹§ããããããªãã
ããŠã€ã«ã¹ã«æŽé²æžã¿ã§ããããšãå ç«ãããããšã¯å¿ ãããçºçãéçåãé²ããããšãæå³ããªããäžæŠå ç«ãç²åŸãããŠãå ç«åãäœäžããã°ææãçºçãéçåãããããšã¯ãããããã¯ã¯ã¯ãã³ãæã£ãŠãåãã§ããã
ãäžæçããã°é¢šéªã¯äœåºŠã§ãåŒãããšã¯å€ãã®äººã身ããã£ãŠç¥ã£ãŠããã¯ãã ã
ãæ¥æ¬ã®PCRéœæ§è æ°ã»å ¥é¢æ£è æ°ã¯1æ8æ¥ã«ããŒã¯ãéãããã®åŸæžå°ã®äžéã§ããã
ãã®ããŒã¯ã¯å
ã«æãã2019幎1æä»¥åã®ã·ãŒãºã³ã®ã€ã³ãã«ãšã³ã¶ã®ããŒã¯ãšããã¿ãªéãªãã
ãäŸå¹Žãã®ææã¯äººã®å
ç«åãäœäžããããã颚éªãæµè¡ãã®ã ã
ãããã¯æ¥æ¬ã ãã§ã¯ãªããååçã®å€ãã®åœã§ããã¿ãªåã1æ8æ¥ã«ææè æ°ã»æ»è æ°ãšãããŒã¯ã¢ãŠãããŠãããååœã®ææç¶æ³ã»ææå¯Ÿçã®éãã«å šãé¢ä¿ãªãã
ãããã¯å¬è³ãéããæ¥ç
§ãå¢ããŠãããšããå°çèŠæš¡ã®çç±ã§ãã説æãã€ããªãã
ããŸãäžçäžã»ãšãã©ã®åœã§ææè æ»è ãæžå°ããŠããã®ã¯ãäžè¬ã«ææçã¯æéçµéãšãšãã«å ç«ç²åŸãã人ãå¢ããå ç«åã匱ãäººã¯æ»ã«çµãããç åäœã¯å ±çããããã«åŒ±æ¯åã«åããåŸåãããããã§ãããã
ãããããå€ã«åããæ¥ç
§ãå¢ããååçã§ã¯åºæ¬çã«çºçã»éçåã¯æžããå¬ã«åããæ¥ç
§ãæžãååçã§ã¯åã³çºçã»éçåãšãããçšåºŠå¢ããã ããã
ãããã§ãæšå¹Žãã被害ã¯å°ãªããªãã¯ãã ã
ãäœèšãªããšããããªããã°ã
3. ã€ã¹ã©ãšã«ã§ææè æ»è ãæ¿å¢ãããã
ãäžçäžãããŒã¯ã¢ãŠãããäžãäŸå€çã«ææè æ°ã»æ»è æ°ãæ¿å¢ãããåœãïŒã€ããã
ãä»ã§ããªãããã¡ã€ã¶ãŒç€Ÿã®ãã³ãããã£ç泚ããã»ãšãã©ã®åœæ°ã«æ³šå
¥ãçµãããšããã€ã¹ã©ãšã«ã§ããã
ã12æ19æ¥ã«ãã³ãããã£ç泚ãã®æ³šå
¥ãéå§
ã1æ20æ¥ã«ããŒã¯ã¢ãŠãããè¿ãããã®ã®ããŸã 1æ¥ã®ææè
æ°ã¯æ³šå
¥éå§å12æ18æ¥ã®ïŒå以äžãæ»è
æ°ã¯æ³šå
¥éå§åã®3å以äžåºãŠããã
ããŸã å€ããæ¥çš®ããŠããªãä»ã®åœãææè ã»æ»è ãæžãããŠããã®ã«ã€ã¹ã©ãšã«ãå¢ãããŠããã®ã ããããã¡ã€ã¶ãŒç€Ÿã®ãã³ãããã£çæ³šãæ³šå ¥ããäœèšãªããšãã§ãã£ãå¯èœæ§ã倧ã ã
ãã¡ãªã¿ã«ãã¯ã¯ãã³ãæªæ³šå ¥ã®ãé£ã®ãã¬ã¹ããã§ã¯åææã«ææè ã»æ»è ãšãæžå°ããŠããã
ããããªããšã¯ããããããã³ãããã£ç泚ãã¯95%æå¹ã®è«æãåºãŠããã§ã¯ãªããïŒ
ã確ãã«ãããããã§ã¯äºå®ãããããã®ãïŒãããšãè«æãããããã®ãïŒ
ãBMJã®å¯ç·šéé·Peter Doshiå士ã¯ãè«æããããããšèšã£ãŠãããæ§ã ãªçµ±èšããªãã¯ã䜿ã£ãŠ95%æå¹ãšããæ°åãã§ã£ã¡äžããçãããããšãããå ·äœçã«ã¯äŸãã°ã³ãããã£æäžçŸ€ã®è¢«éšè ãçºç±ããããã®å€ããPCRãåããããããšãªãé€å€ããã®ã ã
ãæ¥æ¬èªã§ã®è§£èª¬ð
â¡ãªã¹ã¯ã倧ãããã
ãã€ã¹ã©ãšã«ã®äºå®ããããŠãã®æå¹æ§ã謳ãè«æãæé ã«è¿ããã®ã§ãããšããçãããããã¡ã€ã¶ãŒç€Ÿã®ãã³ãããã£ç泚ãã®ä¿¡ææ§ã¯ãšãŠãäœããšèšããããåŸãªãã
ãããã«æå¹ã§ãªãã ãã§ãªããå±éºã§ããæããããã
ãã¢ã¡ãªã«ã§ã¯æ¢ã«3000äžäººä»¥äžããã³ãããã£ç泚ããäžå¿ã«ãã¯ã¯ãã³ããæ³šå
¥ããããã¡1170äººãæ»äº¡ãããšå ±éãããŠããã
ãä»ã®ãšãããæ¥çš®éå§ãã2ã¶æä»¥å
ã®æ»äº¡ç0.003%ãšã®ããšã(远èšåç
§)
ããããé«ããšèããããäœããšèãããïŒ
ãæ°åã³ãããŠã€ã«ã¹ææçã®æ»äº¡çãšæ¯èŒããŠã¿ããã
ãåè¿°ããããã«ãSARS-cov-2ã¯æ¢ã«æ¥æ¬äººã®å€§åãæŽé²ãããŠããããããŠæ€æ»ããã«ãŠã³ããããããã«ãªã£ãŠãã1幎ãPCRéœæ§è
ã®æ»è
æ°ã¯2æ14æ¥ãŸã§ã®å ±åã§6,950人ããããæ¥æ¬äººå£ã§å²ã£ãæ»äº¡çã¯0.005%ã«ãªãã
ãæ°åã ãèŠããšããã³ãããã£çæ³šãæ³šå
¥åŸã®æ»äº¡çãããã³ããææã®æ»äº¡çã®æ¹ããããã«é«ãèŠããã
ããããããã³ãããã£ç泚ãã®æ»è
æ°ã¯2ã¶æä»¥å
ãæ¥æ¬ã®æ»è
æ°ã¯1幎éã§ããã
ããŸããã³ãããã£ç泚ãã®æ»è
æ°ã¯çŽæ¥æ»å ãšããŠçãããŠãããã®ã ãã§ããã®ã«å¯Ÿããæ¥æ¬ã®ã³ããæ»è
æ°ã¯æ»åŸæ€æ»ãå«ããPCRéœæ§æ»è
æ°ã§ãããæšå¹Ž6æ18æ¥ã®ååŽçéé以éãç±äžçãèè¡°ãäºæ
æ»ãèªæ»ã蟌ã¿ã®æ°åã§ããã
ããŸããã³ãããã£ç泚ãã®æ»è
ã¯å¥åº·ãªè¥ãäººã®æ»ãè€æ°å ±åãããŠããããæ¥æ¬ã®COVID-19ã®æ»è
ã¯80æä»¥äžã®æç
ãæã€äººã倧åã§ããã
幎代å¥äººå£ãããæ»äº¡çãèšç®ãããšã2ã¶æéå¹³åã®æ»äº¡çããã³ãããã£ç泚ãã®æ»äº¡ç0.003%ãè¶ ããã®ã¯80代以äžã ãã70代ã§ããã³ãããã£ç泚ãã®æ»äº¡ãªã¹ã¯ã®æ¹ãPCRéœæ§æ»äº¡çã®2åé«ãã
ãä»®ã«ãã³ãããã£ç泚ããæå¹ã§COVID-19ã®æ»äº¡ã100%æžãããšããŠããæ¥æ¬ã®80ææªæºã§ã¯ãã®ã¡ãªãããããã³ãããã£ç泚ãã§æ»äº¡ãããªã¹ã¯ãé«ããšããããšã ã
ããŸãããã¯ãããŸã§ããã³ãããã£çæ³šãæ³šå ¥éå§ããïŒã¶æä»¥å ããã®ã»ãšãã©ãæ³šå ¥ããæ°æ¥ä»¥å ã«ç°åžžããããæ»äº¡ãå ±åãããäŸã«éã£ãæ°åã§ãããé·æçãªã¹ã¯ã«é¢ããŠã¯äœã®ããŒã¿ãååšããªãã
ããã®çåœã®ã»ã©ã¯å®ãã§ã¯ãªãããªããªããŸã 14é±éçµã£ãŠããªãããã ã
ãã ãã誰ãåŠå®ã§ãããå®å
šã ãšèšãããšã¯ã§ããªããããã¯ãªã¹ã¯ããããããšããããšã ã
å®å šãã©ããããããªããã®ã¯ãå®å šã ãšã¯èšããªãã
ããããåŸæ¥ã®ã¯ã¯ãã³ã§ããçã¯ã¯ãã³ã¯æ»äº¡çãäžããããäžæŽ»åã¯ã¯ãã³ã¯å
šäœã®æ»äº¡çã倧å¹
ã«äžããããšãå ±åãããŠããã
COVID-19ã®æ»äº¡çã ãã§ãªããæ¥çš®ããäººãšæ¥çš®ããŠããªã人ã®å¥åº·ç¶æ ãæ»äº¡çãæ¯èŒããªããŠã¯æã£ãæ¹ããããšã¯èšããªãã
â¢ããããã¯ã¯ãã³ã§ã¯ãªããã
ãå®ã¯ããã¡ã€ã¶ãŒç€Ÿã®ãã³ãããã£ç泚ãã¯ããããã¯ã¯ãã³ã§ã¯ãªãã
ãæ¿åºãã¹ã³ãã¯ãã¯ã¯ãã³ããšé£åŒããŠæ¥çš®ãåŒã³ãããŠãããããã³ãããã£ç泚ãã¯ã¯ã¯ãã³ãšã¯äŒŒãŠéãªããã®ã ã
å€èŠãåŒã³åã䌌ãŠããŠãæ¬è³ªçã«ã¯å šãç°ãªããã®ã¯ãã®äžã«æ°å€ãååšãããããã«ããŸããè¹ã§ã¯ãªãããããªããããã«é°»ã¯å«ãŸãããããããããªãã§ãã¯ãå§ããã§ã¯ãªãã
ããããŸã§ãã¯ã¯ãã³ããšã«ã®ã«ãã³ãã€ãããæ¥çš®ãã§ã¯ãªããæ³šå ¥ããšèšã£ãŠããã®ã«ã¯çç±ãããã®ã ã
ãããããã¯ã¯ãã³ãšã¯äœãïŒ
ã¯ã¯ãã³ãšã¯ã匱æ¯ã®ç åäœãã®ãã®(çã¯ã¯ãã³)ãããã¯ç åäœããäœãããç¡æ¯åãããã¯åŒ±æ¯åãããæåïŒäžæŽ»åã¯ã¯ãã³)ãæäžããããšã§ãææçã«å¯Ÿããå ç«ãç²åŸããããšãä¿ãè¬å€ã§ããã
ãã³ãããã£ç泚ãã«ã¯ã匱æ¯åããããŠã€ã«ã¹ããã®æåã¿ã³ãã¯ãå«ãŸããŠããªããïŒè±åïŒCOMIRNATYãCOVID-19ãmRNAãã³ãã¥ããã£[community]ãå ç«[immunity]ãšããçšèªãçµã¿åããã補ååãã¹ãã«çã«ã¯ã©ã¡ãããšãããšãã³ãã«ããã£ããšçºé³ãããã¹ãã§ãã€ã«ãããã£ãšã³ãã¥ããºã [å ±ç£äž»çŸ©]ã圷圿ãšãããããã®ã¯ç§ã ãã ãããïŒïŒ
äž»æåã¯mRNAãå³ã¡éºäŒåã§ããã
ã€ãŸããã³ãããã£ç泚ãã¯ã¯ã¯ãã³ã®å®çŸ©ããå€ãããå ç«ç³»ã¯ãããŸã§ãã¿ã³ãã¯è³ªãåŠç¿ããŠæäœãç£çããã®ã§ãã£ãŠãmRNAãåŠç¿ããããšã¯ãªãã
mRNAã¯æ¬æ¥ã³ãããŠã€ã«ã¹ãã€ããããã¹ãã¹ãã€ã¯ã¿ã³ãã¯è³ªã人äœã«ã€ãããããããããäžäœäœãæå³ããã®ããŸã æªç¥æ°ã§ããã
ãã¡ã€ã¶ãŒç€Ÿã¯ããã¯ã¯ãã³ã補é ãã補è¬å瀟ã¯ãã¯ã¯ãã³ã«ãã£ãŠäœããã£ãŠã責任ãåããªãããšãååœæ¿åºã«äºæ¿ãããŠãããïŒæå¹æ§ã«ãå®å šæ§ã«ãèªä¿¡ããªãããã ãããããªãã¯é£ã¹ãåã«ãè ¹ãå£ããŠãæ»ãã§ã責任åããŸããããšç¢ºçŽãããåºã§é£äºããã ãããïŒïŒ
ããã©ãžã«ã®ãã«ãœãã倧統é ã¯ãããè©ããŠãã¯ã¯ãã³ãæã£ãŠç¿æã¯ãã«ãªã£ãŠãããšããŠãæå¥ã¯èšããªãããšèšã£ãã
ããããããªãmRNAãæ³šå ¥ããã®ãïŒ
ãã³ãããŠã€ã«ã¹ã®ã¿ã³ãã¯è³ªã¯å€ç°ãå€ãããã ãšèšãããããã¿ã³ãã¯è³ªãå€ç°ããã®ã¯ãããŸã§ãã®èšèšå³ã§ããéºäŒåãå€ç°ããããã§ãå šãçç±ã«ãªã£ãŠããªãã
ãèšãèš³ããŠãœã§ããããã«ã¯ãè£ã«ã¯çã®ç®çãããã¯ãã ã
人äœå®éšã»ç€ŸäŒçå®éšãšèšã人ãããã
ãããã¯éãã
å®éšã¯ãå¿ ãæ¯èŒå¯Ÿè±¡ãå¿ èŠãšãããè¬ç©ãªããæäžããäººãšæäžããªãã£ãäººãæ¯èŒããŠãã®æå¹æ§ã»å®å šæ§ã確èªããã®ãå®éšã ã
ãæ¯èŒããªããã°ãããæå¹ãªã®ãæå®³ãªã®ãå€å®ã®ãããããªãã
ãã¹ã¯ãããã¯ããŠã³ãããªãã¹ãŠã§ãŒãã³ãPCRãããæ®éã«çµæžãå¶ãã¿ã³ã¶ãã¢ããããããç§ãã¡ã¯ãããã®ãææå¯Ÿçããæå®³ç¡çã§ãã£ããšãããã
âïžPCRããããã¿ã³ã¶ãã¢ã
ããšããããã³ãããã£ç泚ããã¯ããã³ãããã¯ã¯ãã³ãã®å€ãã¯å¯Ÿè±¡çŸ€ãèšããã«ãæ³çã«ã§ããå調å§åã§ãããåã°åŒ·å¶çã«å šå¡ã«æ³šå ¥ããŠããã
ããã¯å®éšã§ã¯ãªããåãªãã宿œãã§ãããïŒè¿œèšïŒãã¡ã€ã¶ãŒè£œã¯å®ã¯ïŒçš®é¡ããããã§åœŒãã«ã¯å®éšãªã®ãããããªããããã®çµæãæããã«ãããããšã¯ãªãããïŒ
ãå šå¡ã«æãããããšããã®ã¯ãæã£ã人ã«è¢«å®³ãåºãŠæããªã人ãç¡äºã§ãã£ãããã¯ã¯ãã³ãã被害ã®åå ã§ãããšããã£ãŠããŸãããã ã
ãããããå®éšããšåŒã¶è ã¯ç§åŠè ãšããŠå šãä¿¡çšã§ããªãã
ããã®ç®çãäœãªã®ããç§ã«ã¯ç¢ºèªãããã¹ããªãã
ããããé°è¬è«ããšèšãããå°ç人å£åæžã®ãããããã®ããã«å€ãã®å¥³æ§ãäžåŠã«ãããããšãããCOVIDãã®çã®æå³ã¯ãCertification Of Virus IDã (ãŠã€ã«ã¹IDã®èªèšŒ)ãšèšããããããªç®¡ç瀟äŒããããããããªã®ããç§ã«ã¯ããããªãã
ãããä»®ã«ããã ãšããŠããæãããåŽã§ãããèªãã人ã¯ããªãã ããããèªãããªã誰ãèªåãå®¶æã«æãããªãã ãããïŒãã³ãããã£ç泚ããã€ããããã¹ãã€ã¯ã¿ã³ãã¯ãèç€ã®åœ¢æãé»å®³ããããšããªãŒã¯ãããã¡ã€ã¶ãŒç€Ÿã®å
å¯ç€Ÿé·Mike Yeadonæ°ã®ãã€ãã¿ãŒã¢ã«ãŠã³ãã¯åçµãããããã ïŒ
ããã å°ãªããšããŠãœãã€ããŠé ããŠããããã«ã¯ãç§ãã¡ã®å¹žãã«ã¯ã€ãªãããªãããã§ããªãç®çã§ããããšã¯ãããã
æ¥æ¬ã§ã¯ãã³ãããŠã€ã«ã¹ã«ãã£ãŠé«ã å¹Žéæ°å人ã®é«éœ¢è ãæ»äº¡ããçšåºŠã§ãããããã¯æ¥æ¬ç€ŸäŒã«ãšã£ãŠåé¡ã§ãããªãããããŸã§ããã£ãšç¹°ãè¿ãããŠããèªç¶ãªããšã ã(ãã³ãã³ã³ããªãçæ³ãªãããã³ãã³ã³ããã§ãããã¯ãã ïŒ
ãããä»®ã«ãã³ãããã£ç泚ãã女æ§ãã¡ãäžåŠã«ããã°ãå šå¡ãæ¥çš®ãããåœãæ°æã¯çµ¶æ» ããããšã«ãªããïŒæ¥æ¬ã¯ããã§ãªããŠãäžåŠçã®å¢å ã«æ¯æ¢ããããããªãã®ã«ïŒ
ãããã«ããŸãããããªããããã¯å®äŸ¡ã«è¹ãé°»ã®çŸå³ãããæäŸããããšãç®çãšããŠãããããªãã§ãã¯ãã®äººã®çãæ¹ã§ãããã®ç®çã¯æç¢ºã§ãããïŒç§ã¯ãã®ååšãå
šãåŠå®ããªãïŒ
ãäžæ¹ããã³ãããã£ç泚ãã¯ããã³ãããã¯ã¯ãã³ãã®ç®çã¯åŸäœãç¥ããªãã
ã以äžã
â ã¡ãªããããªããã
â¡ãªã¹ã¯ã倧ãããã
â¢ããããã¯ã¯ãã³ã§ã¯ãªããã
ãã®ïŒã€ã®çç±ããããã¡ã€ã¶ãŒç€Ÿã®ãã³ãããã£ç泚ããã®ä»ã®ã³ãããã¯ã¯ãã³ããæããªãã
ããããç§ã®éžæã§ããã
ã
远èšïŒ
远èšïŒïŒå
ã
ã³ããæ»è
ãŒããææè
ãã»ãšãã©ããªãã£ãã®ã«ãªãããã¯ã¯ãã³ãæ¥çš®ãå§ããã»ãŒã·ã§ã«ããã¯ã¯ãã³ã泚å
¥éå§ããææè
ãæ¥å¢ãæ»è
ãåºå§ãããæ°ã¯å°ãªããã人å£86,000人ããããªããããæ¥æ¬äººå£ã«æç®ãããšæ³šå
¥éå§ããçŽïŒã¶æã§1äžäººä»¥äžãæ»ãã ããšã«ãªãã
远èšïŒæ»äº¡1170äººã»æ»äº¡ç0.003%ã®æ°åã¯2æ11æ¥ã®CDCã®å ±åã§ããè€æ°ã®ã¡ãã£ã¢ãCDCã®ã¹ã¯ãªãŒã³ã·ã§ããä»ãã§åãæ°åãå ±ããŠããŸãã
æ¥çš®äººæ°ã¯æ»äº¡è
1,170人÷0.003%=3,900äžäººã§ãã
CDCãµã€ãã¯æ¢ã«æŽæ°ãããã®æ°åã¯èŠåœãããŸããã
çŸåšã®æ°åã¯2æ14æ¥ãŸã§ã®å ±åãšããæ»è 934äººãæ»äº¡ç0.0018%ãšã®ããšãããã§ããŸã æ¥æ¬ã®70代ã®PCRéœæ§æ»äº¡çãäžåããŸãã
远èšïŒããã£ãïŒããããããã£ãïŒã¯ã¯ãã³æã¡ãããªããªã£ãïŒæããªããšæ±ºæããïŒãšããæ¹ã¯ãã²ã¹ãâ€ïžãã¿ã³ãæŒããŠãã ãã^^
















